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Pathophysiology of cardiovascular disease in hemodialysis pa- to the high mortality of ESRD patients. Macrovascular
tients. Cardiovascular disease is the principal cause of morbid- disease develops rapidly in uremic patients and is respon-
ity and mortality in dialysis patients. The principal alterations sible for the high incidence of ischemic heart diseaseresponsible are left ventricular hypertrophy and arterial disease
[1, 2]. Although the majority of these accidents may becharacterized by an enlargement and hypertrophy of arteries
due to atherosclerotic obstructive lesions, in 25 to 30%and the high prevalence of atheromatous plaques. Left ventric-
ular hypertrophy is the consequence of combined effects of of these patients its origin is nonatherosclerotic, being
chronic hemodynamic overload and nonhemodynamic biochem- associated with microvascular disease or fibroelastic
ical and neurohumoral factors characteristic of uremia. The thickening of the aorta and reduced arterial compliancehemodynamic overload is due to flow and pressure overload.
[3, 10, 11] associated with nonatherosclerotic arterial re-The flow overload is tightly related to hyperkinetic circulation
modeling [11–14]. The cardiac and vascular abnormali-caused by anemia, arteriovenous fistula, or overhydration and
is characterized by an enlargement of the left ventricular cavity. ties share several common pathophysiological mecha-
The pressure overload in these patients is more tightly related nisms and are frequently interrelated [11]. The purpose
to abnormal geometry and function of large conduit arteries,
of the present article is to summarize the pathophysiolog-principally the stiffening of arterial tree. The flow overload is
ical mechanisms of cardiac and arterial alterations inalso in large part responsible for remodeling of arterial tree, and
as the heart and vessels are a coupled interactive physiological ESRD patients undergoing replacement therapy.
system, cardiac and vascular alterations occur in parallel, being
induced to a great extent by the same hemodynamic abnormali-
ties. The principal clinical consequences of left ventricular hy- PATHOPHYSIOLOGY OF
pertrophy and arterial alterations are heart failure, ischemic CARDIAC HYPERTROPHY
heart disease, and peripheral artery disease. Cardiovascular
Left ventricular hypertrophy is an adaptive responsealterations are only partly reversible, and efforts should be
directed toward early prevention. to increased cardiac work (Fig. 1). The initiating signal
includes myocardial stretch increasing the LV tensile
stress [15, 16]. Increased cardiac work is frequently asso-
Cardiovascular disease is the leading cause of mortal- ciated with increased release of neurotransmitters and
ity among patients with end-stage renal disease (ESRD), vasoactive substances that may have a permissive or di-
with cardiac disease alone accounting for 40% of deaths rect effect on cardiomyocyte growth [17, 18]. LVH is both
[1, 2]. Cardiomyopathy and ischemic heart disease are beneficial and detrimental. The benefit is linked to an
the most frequent causes of cardiac death [3–5]. At all increased number of sarcomeres, enhancing the working
ages, dialysis patients are at a 10- to 20-fold increased capacity while keeping the parietal tensile stress stable,
risk of death from a cardiovascular cause, with the rela- thus sparing energy [17, 18]. This beneficial effect main-
tive risk being higher in younger patients and declining tains normal systolic function during the initial phase of
with age [2]. Left ventricular hypertrophy (LVH) is the compensated “adaptive” LVH. The sustained overload
most frequent cardiac alteration in ESRD and is an inde- leads progressively to “maladaptive” hypertrophic re-
pendent risk factor for survival in these patients [6–9]. sponse [16]. In the maladaptive phase of LVH, the active
Epidemiological and clinical studies have shown that myocardial cells have an imbalance between energy ex-
damage of large arteries is a major contributory factor penditure and production, resulting in a chronic energy
deficit and accelerated death of myocytes [15, 16]. The
increase in extracellular matrix and collagen content per-Key words: heart failure, intensive care, dialysis mortality, arterial dis-
ease, left ventricular hypertrophy. mits maintenance of the mechanical efficiency of the
contracting heart at the expense of impaired diastolicÓ 2000 by the International Society of Nephrology
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in the relative wall thickness of the LV [6]. In stable
patients with compensated hypertrophy, the systolic
function remains in the normal range, while the diastolic
filling is frequently altered [6–8].
Left ventricular hypertrophy in ESRD patients is prin-
cipally due to an increase in LV minute work resulting
from volume and pressure overload [8, 20]. Nevertheless,
experimental and clinical studies demonstrated that the
cardiovascular structural changes in ESRD are in part
independent from hemodynamic factors [21–25]. In ex-
perimental renal failure, increased cardiac mass with in-
terstitial fibrosis [26], reduced capillary density, and in-
creased intramyocardial arteriolar wall thickness has
been demonstrated [27, 28]. Experimental studies have
shown that parathyroid hormone could have a permis-
Fig. 1. Correlation observed in ESRD patients between stroke work sive role in the cardiac fibrogenesis and the activation
index and left ventricular mass index (r 5 0.62; P , 0.0001). of cardiac fibroblasts [21]. Cardiac remodeling in experi-
mental uremia is characterized by activation of postmi-
totic cardiomyocytes [22], possibly predisposing to apo-
ptosis and “maladaptive” hypertrophy [29]. The LV offilling. LVH usually develops in a pattern specific to the
ESRD patients is characterized by an expansion of theinitiating mechanical stress [15, 16]. Pressure overload
cardiac interstitium. The latter is more prominent than inresults in a parallel addition of new sarcomeres with a
patients with diabetes or primary essential hypertensiondisproportionate increase of the LV wall thickness and
with comparable LV mass [26]. Intramyocardial fibrosisnormal chamber radius (concentric hypertrophy). Vol-
in hemodialyzed patients with secondary hyperparathy-ume overload results primarily in the addition of new
roidism could account for the development of an inade-sarcomeres in series and secondarily in the addition of
quate hypertrophy with persistence of high LV systolicsarcomeres in parallel, resulting in an enlargement of the
stress [30]. Nevertheless, the role of hyperparathyroidismLV chamber with an increased wall thickness sufficient to
is controversial, and parathyroidectomy did not producecounterbalance the increased radius (eccentric hypertro-
significant effects on cardiac structure and functionphy) [15]. The development and characteristics of LVH
[31–33]. With some exception [24], an association ofare influenced by several other factors, such as age, gen-
LVH and plasma renin-angiotensin activity was not dem-der, race, and coexistent diseases like diabetes, systemic
onstrated [23]. Nevertheless, angiotensin I-convertingdiseases, or renal failure.
enzyme (ACE) inhibitors are able to partially regress
LVH independently of their antihypertensive effect, sug-
CARDIAC HYPERTROPHY IN gesting that the tissular and cardiac renin-angiotensin
DIALYSIS PATIENTS system could play a role in the pathogenesis of LVH in
uremic patients [23]. A recent study by Demuth et alThe prevalence of LVH is high among ESRD patients.
The structural alterations occur early in the course of showed that the increased plasma endothelin in ESRD
patients was associated with LVH, suggesting that endo-renal failure. In a prospective study in patients starting
renal replacement therapy, 74% of the patients had LVH, thelin may be of pathophysiological significance in the
process of cardiac remodeling [25]. The influence of en-and high LV mass index was an independent predictor
of death after two years of treatment [19]. In dialysis dothelin in the cardiac remodeling was also demon-
strated experimentally in rats in which the endothelinpatients, as many as 80% of patients have an increased
LV mass [6–19]. The increase in the LV mass in ESRD receptor antagonists were able to attenuate the develop-
ment of myocardial hypertrophy [34]. Low serum albu-patients can be due to an increase in either LV end-
diastolic diameter or LV wall thickness and combines the min in ESRD was associated with the development of
heart failure in progressive dilation of the LV [4, 7].features of both eccentric and concentric hypertrophy
[4, 6, 8]. The precise classification of LVH as an eccentric The causal mechanisms of this association are not clear.
Hypoalbuminemia could reflect the existence of an in-or concentric type is sometimes difficult in hemodialysis
patients because of cyclic variations in extracellular fluid flammatory state characterized by increased C-reactive
protein, fibrinogen, and cytokines, which are consideredvolume and humoral balance. The internal dimensions
of the LV are influenced by volume status, and the con- as cardiovascular risk factors. In ESRD patients, hypoal-
buminemia is also associated with the presence of athero-traction of blood volume during the dialysis session de-
creases the LV diameter, thus inducing “acute” changes matous plaques [35] and abnormal endothelial function
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changes and LV mass, as well as stroke volume [6, 8,
20]. A progressive and frank LV dilation is observed
in the maladaptive phase of LVH, whatever its origin
(anemia, hypertension, hypoalbuminemia, ischemic heart
disease). In these conditions, the LV systolic function is
depressed with clinical signs of cardiac failure and/or
ischemic heart disease [4].
Pressure overload
In ESRD patients, the correlation between LV mass
and blood pressure (BP) is weak, and experimental and
clinical studies have shown that LVH develops even in
normotensive conditions [6, 8, 23, 44]. Since BP is the
easiest measurable index of opposition to LV ejection,
afterload is usually taken to be a function of the pressure
Fig. 2. Correlation between hematocrit and stroke volume index in against which the LV must eject. BP is an integrated
dialysis patients (r 5 0.27; P , 0.005). nonspecific external load on the LV affected by complex
interactions between the properties of the arterial system
and the characteristics of LV ejection [45]. The ill effects
of hypertension are usually attributed to a reduction in[36]. Hypoalbuminemia may affect endothelial function
the caliber or the number of arterioles, resulting in anand may inhibit nitric oxide (NO)-mediated vascular re-
increase in peripheral resistances. Peripheral resistanceslaxation and LV/vascular coupling [37, 38].
are a determinant (with cardiac output) of mean arterial
pressure, in which the pressure and flow are considered
HEMODYNAMIC FACTORS AND CARDIAC as constant over time. This definition does not take into
HYPERTROPHY IN ESRD PATIENTS account the fact that BP is a cyclic oscillating phenome-
non with systolic and diastolic BP being merely the limitsThree factors are involved: (1) an increased stroke
volume and hyperkinetic high-output state (flow/volume of these oscillations, and that in the arterial system the
mean BP is a virtual pressure. Moreover, systolic BP isoverload), (2) an increased opposition to LV ejection
(pressure overload), and (3) an increased heart rate [5–8]. amplified from the aorta to the peripheral arteries, and
brachial artery systolic BP only indirectly reflects the
Volume/flow overload systolic BP in the aorta and LV [45]. The appropriate
term to define the arterial factor(s) opposing LV ejectionVolume/flow overload is characterized by an increased
stroke volume and cardiac output in association with an is aortic input impedance, which depends on: (1) periph-
eral resistance, (2) the viscoelastic properties of the aortaincrease in the LV end-diastolic diameter [4, 6, 8, 20].
The LV enlargement in ESRD patients is attributable and central arteries, and (3) the inertial forces repre-
sented by the mass of the blood in the aorta and LVto: (1) anemia (Fig. 2), (2) arteriovenous (AV) shunts,
and (3) sodium and water retention [7, 8, 39]. In a recent [45]. Peripheral resistance as a determinant of mean BP
sets the general level at which the pressure wave willprospective study by Levin et al, a decline in the hemo-
globin level was an independent predictor of LV growth fluctuate. The amplitude of the fluctuation (pulse pres-
sure) is influenced by the viscoelastic properties of thein early renal disease [40]. In patients on dialysis therapy,
the correction of anemia with epoetin decreases the hy- aorta and large arteries and by the characteristics of LV
ejection (stroke volume and ejection velocity). Theseperdynamic circulatory state and induces partial regres-
sion of LVH, principally by reducing the internal dimen- viscoelastic properties can be described in terms of com-
pliance, distensibility, or stiffness [45, 46]. Stiffening ofsions of the LV [41–43]. Cardiomegaly with high-output
cardiac insufficiency occurs as a complication of high- arterial walls (decreased compliance and distensibility)
can increase the LV afterload independent of peripheralflow AV shunts. The creation of an AV shunt for hemo-
dialysis access is in part responsible for LV dilation and resistances. This situation is clinically characterized by
a large amplitude of the arterial pressure wave (pulsea high-output state [6, 8]. However, symptomatic cardiac
failure caused by AV shunts alone is uncommon and pressure) caused by high systolic and/or low diastolic
pressure or both [45]. Two mechanisms are involved.occurs more frequently in patients with underlying car-
diac disease. The internal dimensions of the LV, the The first involves generation of high systolic pressure by
the LV ejecting into a stiff arterial system, and a de-stroke volume, and the end-diastolic pressure are directly
related to the circulating blood volume, and there is creased diastolic recoil resulting in lower diastolic pres-
sure. The second acts through the influence of arteriala direct correlation between interdialytic body weight
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Table 1. Cardiac parameters in control subjects and end-stage renal a much higher prevalence of calcified plaques in ESRD
disease patients (ESRD)
patients than in age-matched controls in whom soft
Controls ESRD plaques are more frequent [35]. While ESRD produces
Parameters N 5 82 N 5 110 atherogenic factors essentially unique to uremia, including
LV-EdiD mm 51.064.5 53.565.5a dyslipidemia, calcium-phosphate alterations, malnutrition,
LV-EsyD mm 31.564.5 35.066.0a
and activation of cytokines, these factors are additivePWTh mm 9.361.5 10.562.0a
IVSTh mm 9.462.0 11.062.0a to the number of risk factors observed in subjects with
LV mass index g/m2 109628 163651a preserved renal function, such as age, hypertension, smok-
% shortening 38.065.2 35.066.3a
ing, diabetes, male gender, and insulin resistance. ManyE/A ratio 1.2560.36 0.9860.36a
Stroke index mL/m2 44.066.7 52.0612.0a hemodialysis patients already have significant vascular
Cardiac index mL/min/m2 30086772 35166850a lesions before initiating dialysis, and in many patients,
Total peripheral resistances
especially older patients, the generalized atherosclerosisdyne · s · cm5 ·m2 29726760 25226695a
can be the primary cause of renal failure. HypertensionValues are means 6 standard deviation.
aP , 0.001 is a frequent complication in ESRD, and an association
Abbreviations are: LV-EdiD, left ventricular end-diastolic diameter; LV-EsyD between high BP and occlusive arterial lesions was foundCCA, left ventricular end-systolic diameter; PWTh DP, posterior wall thickness;
IVSTh, interventricular septal thickness. in chronic hemodialysis patients. Rigorous control of
hypertension at the time of incipient renal failure led
to a significant decrease in the incidence of myocardial
ischemia after initiation of dialysis therapy [51].
stiffness on pulse wave velocity (PWV). Arterial stiffen- Besides atherosclerosis and the presence of plaques,
ing accelerates PWV and the propagation of pressure the arterial system of ESRD patients undergoes remod-
waves along the arterial tree. The pressure wave gener- eling that is characterized by dilation and to a lesser
ated in the aorta reaches the peripheral reflecting sites degree, arterial intima-media hypertrophy of central,
earlier and generate a reflected wave, which returns ear- elastic-type, capacitative arteries such as the aorta or the
lier to the aorta, amplifying aortic and ventricular pres- common carotid artery [11–14, 35]. Arterial remodeling
sures during systole and reducing aortic pressure during is less pronounced in peripheral, muscular-type, conduit
diastole [45, 46]. The principal consequences of these arteries, such as the radial artery [52]. In ESRD patients,
changes are the development of LVH and alterations of this remodeling is associated with arterial stiffening [11]
coronary perfusion pressure [45–49]. Total peripheral caused principally by an increase in the Einc (incremental
resistance is usually not increased in patients undergoing elastic modulus), which characterizes the intrinsic prop-
dialysis (Table 1), and the principal factors of pressure erties of wall material. The effect of increased Einc is,
overload are represented by changes in the viscoelastic in part, attenuated by the increase in arterial diameter
properties and geometric properties of the arterial system. [11, 35]. As a consequence of this compensation, the
arterial compliance is usually maintained within normal
range, and the distensibility of capacitive arteries is onlyARTERIAL CHANGES IN DIALYSIS PATIENTS
moderately decreased (Table 2). In uremic patients, the
The remodeling of arterial system in ESRD as well as abnormal arterial stiffening is observed principally in
in the general population is heterogeneous. Atheroscle- younger subjects, since with aging, the effects of age pre-
rosis (development of plaques) and remodeling are asso- dominate over those of uremia [12]. Moreover, in many
ciated with aging (arteriosclerosis) and hemodynamic older ESRD patients, vascular nephropathies occur, and
alterations [11–14, 35]. in these subjects, the arterial alterations are more related
Atherosclerosis and arterial occlusive lesions are the to original arterial disease than uremia per se.
most frequent causes of cardiovascular morbidity in pa-
tients on renal replacement therapy [1, 2]. Occlusive
HEMODYNAMIC FACTORS OF ARTERIALlesions principally involve the medium-sized conduit ar-
REMODELING IN CHRONIC UREMIAteries, and coronary insufficiency, peripheral artery dis-
ease, and cerebrovascular events occupy an important Large arteries, like the aorta or the common carotid
place in the mortality of these patients. The high inci- artery, are enlarged in ESRD patients in comparison
dence of atherosclerosis-related complications led Lind- with age-, sex-, and BP-matched control subjects [11,
ner et al to hypothesize that atherogenesis is accelerated 35, 53]. The internal dimensions of large arteries are
in chronic hemodialysis patients [50]. However, whether influenced by many factors. Several factors are nonspecific
the atherogenesis of dialysis patients is accelerated and for ESRD patients (for example, age, sex, or mean BP),
whether the nature of atherosclerotic plaques is similar in whereas others are more relevant for this patient popula-
hemodialysis patients and the general population remain tion (such as blood-flow velocity and systemic blood flow).
In ESRD patients, chronic volume/flow overload createsmatters of debate. Ultrasonographic studies have shown
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Table 2. Arterial parameters in control subjects and end-stage renal
disease patients (ESRD)
Controls ESRD
Parameters N 5 82 N 5 110
Age years 48.5611.6 50.5614.2
Gender (G/E; G:1; E:2) 1.4060.49 1.3760.48
BSA m2 1.8760.24 1.7160.21c
Systolic blood pressure mm Hg 146.4622.2 149.5627.3
Diastolic blood pressure mm Hg 88.5614.3 84.5614.1
Mean blood pressure mm Hg 107.9615.4 106.9616.9
CCA DP mm Hg 50614 58622b
CCA diameter mm 5.760.8 6.460.9c
CCA DDi lm 3706133 3906145
CCA IMT lm 7006104 7826114c
CCA compliance m2·kPa21·1027 5.362.3 5.562.5
CCA distensibility kPa21·1023 21.169.8 18.068.7a
CCA Einc kPa 103 0.4860.20 0.6360.40c
Values are means 6 standard deviation.
aP 5 0.025 Fig. 4. Correlation between hematocrit and common carotid artery
bP 5 0.005 (CCA) intima media thickness (IMT) in dialysis patients (r 5 0.37; P ,
cP , 0.001 0.0001).
Abbreviations are: BSA, body surface area; CCA, common carotid artery;
DP, pulse pressure; DDi, stroke changes in diameter; IMT, intima-media thick-
ness; Einc, incremental elastic modulus.
tensive patients, Laurent et al have shown that decreased
arterial distensibility was due to higher distending BP
rather than to arterial wall thickening and structural
modifications [57]. In ESRD patients, increased IMT
is accompanied by an increased Einc. This modification
affects elastic and muscular type arteries [11, 52] and is
in favor of altered intrinsic elastic properties or major
architectural abnormalities, namely fibroelastic intimal
thickening, calcification of elastic lamellae, and ground
substance [58, 59]. The reason for uremia-associated
changes in elastic modulus is not clear, and several non-
hemodynamic factors have been implicated.
NONHEMODYNAMIC FACTORS AND
ARTERIAL REMODELING IN ESRD PATIENTS
Arterial remodeling is already observed in patients at
Fig. 3. Correlation between hematocrit and common carotid artery the start of renal replacement therapy and is comparable
(CCA) diameter in dialysis patients (r 5 0.35; P , 0.0001). in patients on peritoneal dialysis and patients treated by
hemodialysis (Table 3). This suggests that nonhemody-
namic factors could play an important role in the patho-
physiology of vascular complications. As shown experi-conditions for arterial remodeling (Fig. 3) [54]. This find-
mentally, the endothelium influences the mechanical anding has been supported by cross sectional studies showing
geometric properties of large arteries, and removing thea relationship between the diameters of the aorta and
endothelium causes an increase in arterial diameter [60].common carotid artery and LV outflow velocity integral
Endothelial function is altered in ESRD patients [61–63],and/or stroke volume [11, 14]. Unlike in BP- and age-
and these alterations are associated with arterial remod-matched nonuremic patients, the arterial intima-media
eling [36]. The role of endothelin in ESRD patients wasthickness (IMT) is increased in ESRD patients [11, 13,
suggested by Demuth et al, who showed an association52]. According to the Laplace’s law, an increase in IMT
between carotid artery IMT and high circulating levelsis proportional to changes in diameter and is partially
of endothelin-1 [25]. Hyperhomocysteinemia has beeninfluenced by the same hemodynamic alterations as
recognized as an important vascular risk factor in thethose influencing arterial diameter (Fig. 4). In ESRD,
general population [64] and was associated with increasedthe increase in arterial IMT is associated with decreased
arterial stiffness [65]. The elevation of plasma totalarterial distensibility, increased PWV, and an early re-
turn of wave reflections [11, 53–56]. In essential hyper- homocysteine (tHcy) in ESRD patients has also been
Meeus et al: Cardiovascular disease in dialysis patients S-145
Table 3. Arterial parameters in hemodialyzed patients (HD) and CLINICAL CONSEQUENCES OF ARTERIAL
patients on peritoneal dialysis (PD)
REMODELING IN ESRD PATIENTS
Parameters HD N 5 95 PD N 5 15 The arterial changes in ESRD are responsible for an
Age years 50615 55614 increased systolic and pulse pressures [2, 11, 72]. In the
Gender (G/E; G:1; E:2) 1.3760.51 1.5060.48
general population, pulse pressure has been shown toBSA m2 1.6860.20 1.7860.24
Systolic blood pressure mm Hg 148627 153629 be a strong predictor for the risk of coronary heart dis-
Diastolic blood pressure mm Hg 85.4613.2 85.0614.0 ease and cardiovascular complications [73–75]. Blacher
Mean blood pressure mm Hg 107.0616.3 108.0617.0
et al applied logistic regression and Cox analyses to theCCA DP mm Hg 57622 63623
CCA diameter mm 6.460.9 6.261.0 characteristics of hemodialyzed patients and identified
CCA DDi lm 3946137 3436192 aortic distensibility (aortic PWV) as a strong and inde-
CCA IMT lm 7706118 8006101
pendent predictor of cardiovascular and overall mortal-CCA compliance m2·kPa21·1027 5.762.5 4.963.3
CCA distensibility kPa21·1023 18.368.6 17.2612.0 ity [76]. PWV is a complex parameter integrating arterial
CCA Einc kPa 103 0.6060.40 0.7560.45 geometry and intrinsic elastic properties described by
Duration of replacement therapy
the Moens-Korteweg equationmonths 86678 22614a
Values are means 6 standard deviation. PWV2 5 Eh/2rr
aP , 0.001
Abbreviations are: BSA, body surface area; CCA, common carotid artery; where E is the elastic modulus (Einc); r is the radius; hDP, pulse pressure; DDi, stroke changes in diameter; IMT, intima-media thick-
ness; Einc, incremental elastic modulus. is the wall thickness, and r is the fluid density [45]. Based
on Cox analyses, Blacher et al have shown that the princi-
pal “hemodynamic” predictors of cardiovascular and all-
cause mortality in ESRD were the elastic modulus and
recognized as an important atherogenic vascular risk fac- dilation of arteries, that is, generalized arterial disease [77].
tor in hemodialysis patients and kidney transplant recipi- Dialysis by itself does not improve arterial distensibil-
ents [66, 67]. Nevertheless, in ESRD patients, the cross- ity [78], and some studies indicate that arterial function
sectional studies have not convincingly shown the type worsens with the time on dialysis [13, 70]. In older essen-
of structural or functional alterations associated with tial hypertensive nonuremic subjects, the long-term anti-
hyperhomocysteinemia. Hyperhomocysteinemia princi- hypertensive therapy induces reverse remodeling with
pally affects atherothrombosis, and its role in nonathero- regression of arterial wall hypertrophy and improvement
matous arterial remodeling is not clear. In the study by of the arterial system viscoelastic properties [79]. Until
Blacher et al, elevated plasma tHcy levels were associ- now, such controlled studies have not been available in
ESRD patients. During recent years, a few controlledated with lower limb artery stiffness, but not with stiffen-
studies aimed at examining the effect of antihypertensiveing of major capacitive arteries like the aorta or carotid
drugs on the function of large arteries have been conductedartery [68]. While the published data agree that smoking
on ESRD patients on hemodialysis. It has been shownis a factor associated with arterial wall hypertrophy and
that calcium-channel blockers lowered BP and decreasedstiffening in ESRD patients [11, 13], no consistent and
aortic and femoral PWV [80]. The same effect on arterialconstant associations could be established between arte-
distensibility was observed by ACE inhibitors [23, 81].rial remodeling and common vascular risk factors. An
However, these studies did not conclude whether theassociation between arterial alterations and low high-
improvement of elastic properties was the consequencedensity lipoprotein cholesterol or high intermediate den-
of the lowered BP or was due to reverse remodeling andsity lipoprotein (IDL) was found in some studies [53,
changes in the intrinsic properties of arterial walls.55, 69]. The most frequently observed factors associated
In conclusion, besides the cardiovascular risk factors
with arterial stiffening in ESRD seem to be alterations
present in the general population, the chronic pressure
in calcium and phosphate metabolism and parathyroid and volume overload are the principal hemodynamic
activity [69–71]. In hemodialyzed patients, aortic PWV factors associated with cardiac and vascular remodeling
was found to be associated with mediacalcinosis of con- in ESRD patients on hemodialysis. Cardiac and vascular
duit arteries and increased calcium-phosphate product alterations evolve in parallel and are tightly interrelated.
[53, 55]. Kawagishi et al reported that a high phosphorus LVH and arteriosclerosis are independent risk factors
level was associated with carotid artery intima-media for overall and cardiovascular mortality in dialysis pa-
thickening (IMT), while increased serum parathyroid tients. LVH can be partially reversed by the control of
hormone was a risk factor for increased wall thickness anemia and BP. Presently available data are insufficient
of femoral arteries [13]. Studying renal transplant recipi- to propose efficient therapeutical intervention for rever-
ents, Barenbrock et al observed an association between sal of arterial alterations, and controlled studies aimed
high parathyroid hormone levels and decreased common at the prevention and/or correction of arterial abnormali-
ties in ESRD patients are needed.carotid artery distensibility [71].
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